Lilly's big bet on Armo sours on phase III pancreatic cancer results Oct. 17, 2019 By Michael Fitzhugh No Comments Eli Lilly and Co.'s $1.48 billion acquisition of Armo Biosciences Inc., intended to broadly bolster its immuno-oncology program, fell short of that goal in its first big test, a phase III trial in second-line pancreatic cancer called Sequoia.Read More